AL622

AL622 is a dual-targeting combi-molecule designed to inhibit both the epidermal growth factor receptor (EGFR) and the non-receptor tyrosine kinase c-Src. Developed by researchers at McGill University, the molecule features a quinazoline head targeted to EGFR connected via a hydrolysable linker to a PP2-like structure targeted to c-Src. AL622 is designed to act as a dual inhibitor in its intact form, while also functioning as a prodrug that undergoes intracellular hydrolysis to release a potent EGFR inhibitor and the c-Src inhibitor PP2. This dual mechanism of action is intended to block the synergistic crosstalk between EGFR and c-Src, which drives cell proliferation, motility, and invasion in aggressive solid tumors, such as breast and prostate cancers.